查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1629900

全球一次性自動注射器市場 - 2025-2033

Global Disposable Autoinjectors Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 159 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年，全球一次性自動注射器市場達到7.123億美元，預計到2033年將達到30.732億美元，2025-2033年預測期間複合年成長率為17.8%。

一次性自動注射器是一種設計用於皮下或肌肉內自我給藥的醫療設備，通常採用預填充注射器的形式。這些設備的特點是一次性使用，這意味著它們在注射藥物後就會被丟棄。使用者只需將自動注射器靠在皮膚上，然後透過簡單的推動即可啟動它。然後，該設備透過隱藏在設備內的針頭自動輸送藥物，針頭在使用後立即縮回，以確保安全並防止針刺傷。

一次性自動注射器市場的需求正在經歷顯著成長。例如，根據美國國立衛生研究院 (NIH) 的數據，已有 20 多家製藥公司開發了近 80 種自動注射器。近 50 種藥物被開發為使用自動注射器給藥的組合產品。其中，62%的自動注射器是一次性的。由於慢性病盛行率不斷上升、藥物配方的進步以及自我給藥的推動等幾個關鍵因素，一次性自動注射器的市場需求一直在穩步成長。

市場動態：

驅動程式和限制

慢性病盛行率上升

慢性病盛行率的上升極大地推動了一次性自動注射器市場的成長，預計將在預測期內推動該市場的成長。隨著全球糖尿病發生率的上升，對自動注射器等胰島素輸送系統的需求不斷增加。例如，根據世界衛生組織 (WHO) 的數據，全球約有 8.3 億人患有糖尿病，其中大多數生活在低收入和中等收入國家。糖尿病患者數量的不斷增加推動了對自動注射器進行胰島素注射的需求，因為自動注射器為患者在家注射胰島素提供了一種方便、更安全的方法，這對於控制病情至關重要。

擴大使用生物製劑和單株抗體來治療自體免疫疾病和癌症，刺激了對自動注射器的需求。這些藥物需要自動注射器提供的精確劑量和可靠給藥。用於治療類風濕性關節炎和其他自體免疫疾病的 Humira Pen 等設備的推出體現了市場對生物製劑的反應，表明對患者友好型自我給藥設備的需求不斷增加。

糖尿病、類風濕性關節炎、多發性硬化症等各種慢性疾病的盛行率不斷上升，由於其便利性和謹慎管理病情的能力，自我給藥的顯著轉變。一次性自動注射器迎合了這一趨勢，允許患者在家中給藥，而無需醫療保健提供者干涉。

例如，2024年1月，大正製藥株式會社宣布推出TNFa抑制劑Nanozora 30 mg一次性皮下注射自動注射器（通用名：ozoralizumab（重組））。此藥物採用的裝置考慮了類風濕性關節炎（RA）患者的易用性。 Taisho 旨在為 RA 患者提供新的治療選擇，提供 Nanozora 30mg 皮下注射注射器和 Nanozora 30mg 皮下注射自動注射器。

替代藥物傳輸系統的可用性

替代藥物輸送系統的出現預計將阻礙一次性自動注射器市場的成長。這些替代方案包括傳統的注射器注射、吸入器和其他形式的藥物輸送，可以提供競爭優勢，例如成本效益、易用性和不同的治療體驗。

傳統注射器仍然是一種具有成本效益的藥物輸送選擇，特別是在資源匱乏的環境中。它們廣泛使用且為醫療保健提供者和患者所熟悉，使其成為一次性自動注射器的有吸引力的替代品。例如，在某些地區，使用一次性自動注射器的成本可能比傳統注射器高得多，這可能會阻礙採用。在預算有限的醫療保健系統中，對傳統注射器的偏好可能會減緩自動注射器的使用。

Auvi-Q 等品牌腎上腺素自動注射器的通用且低成本替代品已獲得關注。這些替代品以較低的價格提供相似的功效，使更廣泛的患者群體更容易獲得它們。這種競爭可能會減少品牌一次性自動注射器的市場佔有率，因為注重成本的消費者會選擇更實惠的選擇。

針對荷爾蒙替代療法和慢性疼痛管理等病症的經皮貼片提供了完全避免注射的替代方案。這些貼片可在較長時間內透過皮膚輸送藥物，無需使用針頭和自動注射器。對此類貼片的日益接受可以減少對一次性自動注射器的需求。例如，治療帕金森氏症的 Neupro 貼片為某些患者提供了自動注射器治療的可行替代方案。

目錄

第1章：市場介紹和範圍

  • 報告的目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按類型分類的片段
  • 按應用程式片段
  • 最終使用者的片段
  • 按地區分類的片段

第 3 章：動力學

  • 影響因素
    • 促進要素
      • 慢性病盛行率上升
      • 不斷進步的技術
    • 限制
      • 替代藥物傳輸系統的可用性
    • 機會
    • 影響分析

第 4 章：策略洞察與產業展望

  • 市場領導者和先驅
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的知名領導者
    • 擁有成熟產品的市場領導者
  • 新興新創企業和關鍵創新者
  • CXO 觀點
  • 最新進展和突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態

第 5 章：一次性自動注射器市場（按類型）

  • 預充式自動注射器
  • 可填充自動注射器

第 6 章：一次性自動注射器市場（按應用）

  • 糖尿病
  • 類風濕關節炎
  • 多發性硬化症
  • 過敏反應
  • 其他

第 7 章：一次性自動注射器市場（按最終用戶）

  • 醫院
  • 專科診所
  • 家庭護理設置
  • 其他

第 8 章：一次性自動注射器市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 9 章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的主要發展
  • 公司基準化分析

第 10 章：公司簡介

  • Becton, Dickinson, and Company
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
    • SWOT分析
  • Ypsomed AG
  • Owen Mumford Inc.
  • Phillips Medisize
  • SHL Medical
  • Stevanato Group
  • Faxne
  • Dali Medical Devices

第 11 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 12 章：附錄

簡介目錄
Product Code: MD8934

The global disposable autoinjectors market reached US$ 712.3 million in 2024 and is expected to reach US$ 3,073.2 million by 2033, growing at a CAGR of 17.8% during the forecast period 2025-2033.

A disposable autoinjector is a medical device designed for the subcutaneous or intramuscular self-administration of medication, which is typically in the form of a pre-filled syringe. These devices are characterized by their single-use nature, meaning they are disposed of after the medication has been injected. The user simply positions the autoinjector against the skin and activates it with a simple push. The device then automatically delivers the medication via a needle hidden within the device, which retracts immediately after use to ensure safety and prevent needle-stick injuries.

The demand for disposable autoinjectors market is experiencing significant growth. For instance, according to the National Institute of Health (NIH), more than 20 pharmaceutical companies have developed nearly about 80 autoinjectors. Nearly 50 drugs are developed as combination products for administration using autoinjectors. Among these, 62% of the autoinjectors are disposable. The market demand for disposable autoinjectors has been steadily increasing due to several key factors including the growing prevalence of chronic diseases, advancements in drug formulations and the push towards self-administration.

Market Dynamics: Drivers & Restraints

Rising prevalence of chronic diseases

The rising prevalence of chronic diseases is significantly driving the growth of the disposable autoinjectors market and is expected to drive the market over the forecast period. With the global rise in diabetes, the demand for insulin delivery systems like autoinjectors has increased. For instance, according to the World Health Organization (WHO), about 830 million people worldwide have diabetes, the majority living in low-and middle-income countries. The rising number of diabetes patients is driving demand for autoinjectors for insulin administration as autoinjectors offer a convenient and safer method for patients to administer insulin at home, which is crucial for managing the condition.

The growing use of biologics and monoclonal antibodies for treating autoimmune diseases and cancer has spurred demand for autoinjectors. These drugs require precise dosing and reliable administration, which autoinjectors provide. The introduction of devices like the Humira Pen for rheumatoid arthritis and other autoimmune diseases exemplifies the market's response to biologics, showing an increased demand for patient-friendly, self-administration devices.

The increasing prevalence of various chronic diseases such as diabetes, rheumatoid arthritis, multiple sclerosis and others is a notable shift towards self-administration due to its convenience and the ability to manage conditions discreetly. Disposable autoinjectors cater to this trend by allowing patients to administer their medications at home without the need for healthcare provider intervention.

For instance, in January 2024, Taisho Pharmaceutical Co., Ltd. announced that the Nanozora 30 mg Disposable Autoinjector for S.C. Injection (generic name: ozoralizumab, (recombinant)), a TNFa inhibitor is launched. The drug employs a device that considers ease of use for patients with rheumatoid arthritis (RA). Taisho aims to provide new treatment options for patients with RA, offering Nanozora 30mg Syringes for S.C. Injection and Nanozora 30mg Autoinjector for S.C. Injection.

Availability of alternative drug delivery systems

The availability of alternative drug delivery systems is expected to hamper the growth of the disposable autoinjectors market. These alternatives, which include traditional syringe injections, inhalers and other forms of drug delivery, can offer competitive advantages such as cost-effectiveness, ease of use and different treatment experiences.

Traditional syringes remain a cost-effective option for drug delivery, especially in low-resource settings. They are widely available and familiar to both healthcare providers and patients, making them an attractive alternative to disposable autoinjectors. For instance, in some regions, the cost of using disposable autoinjectors can be significantly higher compared to conventional syringes, which can deter adoption. In healthcare systems where budgets are limited, the preference for traditional syringes can slow the uptake of autoinjectors.

Generic and low-cost alternatives to branded epinephrine autoinjectors, like Auvi-Q, have gained traction. These alternatives offer similar efficacy at a lower price point, making them more accessible to a broader patient population. This competition can reduce the market share of branded disposable autoinjectors, as cost-conscious consumers opt for more affordable options.

Transdermal patches for conditions like hormone replacement therapy and chronic pain management offer an alternative that avoids injections altogether. These patches deliver medication through the skin over an extended period, bypassing the need for needles and auto-injectors. The growing acceptance of such patches can reduce the demand for disposable auto-injectors. For example, the Neupro patch for Parkinson's disease provides a viable alternative to auto-injector treatments for some patients.

Segment Analysis

The global disposable autoinjectors market is segmented based on type, application, end-user and region.

Product Type:

The prefilled autoinjectors segment is expected to dominate the disposable autoinjectors market share

Prefilled autoinjectors are designed for ease of use, allowing patients to self-administer medications without the need for healthcare provider assistance. These devices typically come pre-filled with the medication, eliminating the need for patients to fill the device themselves. The design of prefilled autoinjectors, such as those used for insulin delivery and other medications, simplifies the administration process and reduces the potential for user error.

For instance, in January 2024, Taisho Pharmaceutical Co., Ltd. launched the Nanozora 30 mg Autoinjector for S.C. Injection (generic name: ozoralizumab, (recombinant)), a TNFa inhibitor. Nanozora 30mg Autoinjector for S.C. Injection is a single-use autoinjector dosage form, prefilled with the same drug as the syringe dosage form Nanozora 30mg Syringe for S.C. Injection. Users can easily inject the drug simply by pressing the injector against the skin. The needle covering will be locked after injection to prevent needle-piercing accidents.

Many prefilled autoinjectors come equipped with smart features such as Bluetooth connectivity for monitoring injection history and dosage reminders. These features enhance patient management and engagement by providing real-time data to patients and healthcare providers. These smart devices also allows patients to monitor their medication usage and receive reminders, making it a preferred choice over traditional devices.

For instance, in May 2022, Stevanato Group S.p.A., a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, signed an exclusive agreement with leading medical device developer and manufacturer Owen Mumford Ltd. for its Aidaptus auto-injector. Aidaptus is a 2-step, single-use auto-injector with a versatile design that accommodates both 1mL and 2.25 mL prefilled glass syringes in the same base device.

Geographical Analysis

North America is expected to hold a significant position in the disposable autoinjectors market share

North America, particularly the United States, boasts a highly developed healthcare infrastructure, which includes advanced hospitals, research facilities, and specialized clinics. This infrastructure supports the adoption of advanced drug delivery technologies such as disposable auto-injectors. For instance, major healthcare providers and facilities across the U.S. utilize auto-injectors for treating conditions like rheumatoid arthritis and multiple sclerosis, which are common in the region. This widespread usage creates a strong demand for disposable autoinjectors.

For instance, in May 2021, Phillips-Medisize, a Molex company, unveiled the Aria Smart Autoinjector platform to unlock innovation, differentiation and sustainability in the digital drug delivery device market. This latest advancement introduces a small smart injection device featuring single-use disposable cassettes to elevate patient care while reducing environmental impact.

In the U.S., self-administration of medications using auto-injectors has been widely adopted for chronic disease management. For example, therapies for rheumatoid arthritis and multiple sclerosis are commonly delivered via auto-injectors like the Sensoready and Rebif, respectively. The convenience and safety of these devices make them highly preferred among patients, contributing to the dominance of North America in this market.

Asia-Pacific is growing at the fastest pace in the disposable autoinjectors market

Countries in the APAC region, particularly China and India, are witnessing substantial increases in healthcare spending as governments allocate more resources towards improving healthcare infrastructure. For instance, China's National Healthcare Security Administration has been expanding insurance coverage to include more advanced medical devices like auto-injectors. This expansion boosts the adoption of these devices across the region.

There is growing awareness among patients in the APAC region regarding the benefits of self-administered therapies. This awareness is being driven by healthcare campaigns, education programs, and the increased availability of auto-injectors through pharmacies and healthcare facilities. For instance, countries like India are seeing increased awareness about the benefits of using prefilled auto-injectors for treating conditions like rheumatoid arthritis.

The younger generation in the APAC region is more inclined towards modern technologies, including those related to healthcare. This demographic trend supports the adoption of auto-injectors over traditional methods. The increasing urbanization and better education levels are also factors contributing to higher acceptance rates of self-administered injectables.

Competitive Landscape

The major global players in the disposable autoinjectors market include Becton, Dickinson, and Company, Ypsomed AG, Owen Mumford Inc., Phillips Medisize, SHL Medical, Stevanato Group, Faxne, Dali Medical Devices and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global disposable autoinjectors market report delivers a detailed analysis with 56 key tables, more than 52 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Chronic Diseases
      • 3.1.1.2. Rising Technological Advancements
    • 3.1.2. Restraints
      • 3.1.2.1. Availability of Alternative Drug Delivery Systems
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Disposable Autoinjectors Market, By Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 5.1.2. Market Attractiveness Index, By Type
  • 5.2. Prefilled Autoinjectors*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Fillable Autoinjectors

6. Disposable Autoinjectors Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Diabetes*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Rheumatoid Arthritis
  • 6.4. Multiple Sclerosis
  • 6.5. Anaphylaxis
  • 6.6. Others

7. Disposable Autoinjectors Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Homecare Settings
  • 7.5. Others

8. Disposable Autoinjectors Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Becton, Dickinson, and Company*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Ypsomed AG
  • 10.3. Owen Mumford Inc.
  • 10.4. Phillips Medisize
  • 10.5. SHL Medical
  • 10.6. Stevanato Group
  • 10.7. Faxne
  • 10.8. Dali Medical Devices

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us